Medication info
S-OL Plus Tablet

S-OL Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Samick Pharmaceutical Co., Ltd.
Appearance
Light yellow circular film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201101861 · Approved 2011.03.31 · Insurance code 644003150

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Before administering this drug, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted individually. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this drug once daily, with or without food. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked blood pressure-lowering effect may occur when olmesartan medoxomil is added or when switching to this drug (olmesartan medoxomil/hydrochlorothiazide) in patients taking high-dose hydrochlorothiazide monotherapy and in patients with volume depletion or hyponatremia. In such cases, the dose of hydrochlorothiazide should be reduced to 12.5mg before olmesartan medoxomil is added. <Elderly patients> In elderly patients, start at the lowest dose and exercise caution when adjusting the dose, taking into consideration the patient's renal or cardiac function, comorbid diseases, and other concomitant medications. <Patients with renal impairment> This drug (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). This drug (olmesartan medoxomil/hydrochlorothiazide) should not be administered to patients with more severe renal impairment, since loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> Use of this drug is not recommended in patients with hepatic impairment because there is no experience with its use in these patients.
Child dose
<Pediatric patients> Safety and efficacy in pediatric patients have not been established.

Ingredients

Manufacturer
Samick Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Olmesartan medoxomil and hydrochlorothiazide are used together when monotherapy is insufficient for blood pressure control in patients with essential hypertension, effectively lowering blood pressure. Each component contributes to lowering blood pressure, thereby reducing cardiovascular risk. This drug combination plays an important role in stabilizing blood pressure management and improving the overall health of the patient, thus used for the treatment of essential hypertension.

How to take

Adult dose

Before administering this drug, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted individually. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this drug once daily, with or without food. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked blood pressure-lowering effect may occur when olmesartan medoxomil is added or when switching to this drug (olmesartan medoxomil/hydrochlorothiazide) in patients taking high-dose hydrochlorothiazide monotherapy and in patients with volume depletion or hyponatremia. In such cases, the dose of hydrochlorothiazide should be reduced to 12.5mg before olmesartan medoxomil is added. <Elderly patients> In elderly patients, start at the lowest dose and exercise caution when adjusting the dose, taking into consideration the patient's renal or cardiac function, comorbid diseases, and other concomitant medications. <Patients with renal impairment> This drug (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). This drug (olmesartan medoxomil/hydrochlorothiazide) should not be administered to patients with more severe renal impairment, since loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> Use of this drug is not recommended in patients with hepatic impairment because there is no experience with its use in these patients.

Child dose

<Pediatric patients> Safety and efficacy in pediatric patients have not been established.

Precautions

This drug can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to any of the ingredients or hypersensitivity to certain diuretics, those with severe renal or hepatic impairment, and pregnant or breastfeeding women should not take this medication. Patients with decreased blood volume or body salt may experience hypotension, so it is important to monitor their condition prior to administration and observe blood pressure and renal function closely during treatment. Patients with impaired renal function, kidney transplant patients, those with renovascular hypertension, and patients with liver dysfunction require special caution when taking this drug, as symptoms may worsen; they should consult their healthcare provider. This medication may cause sensitive skin reactions, so it is advised to avoid sun exposure, and immediately inform healthcare professionals if any skin issues arise. Symptoms such as dizziness, headache, dyspepsia, rash, hypotension may occur during treatment, so if these symptoms persist or worsen, consult a doctor. This drug may interact with other medications, so if you are currently taking any other drugs, be sure to inform your healthcare provider, especially when used together with potassium supplements, diuretics, lithium, non-steroidal anti-inflammatory drugs. Women who are pregnant or breastfeeding should ensure consultation with a healthcare professional before using this drug, and during breastfeeding, it is safest to avoid use or discontinue nursing. The safety of this drug in children has not been established; therefore, it is recommended that children do not take this medication. Elderly patients may experience decreased kidney and liver function, so it is advised to start at a low dose and closely monitor their condition during treatment. In case of overdose, hypotension, electrolyte imbalance, or dehydration may occur, requiring immediate medical attention for appropriate treatment. It is important to regularly monitor blood pressure and perform blood tests to check electrolyte status and renal function while taking this medication.

Side effects

Nausea, hyperuricemia, dizziness, upper respiratory infection, headache, urinary tract infection, chest pain, low back pain, peripheral edema, vertigo, abdominal pain, dyspepsia, gastroenteritis, diarrhea, elevated AST, elevated GGT, elevated ALT, hyperlipidemia, increased creatine phosphokinase, hyperglycemia, arthritis, arthralgia, myalgia, cough, rash, hematuria, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, hyperkalemia, rhabdomyolysis, acute renal failure, increased serum creatinine, hair loss, pruritus, urticaria, palpitations, hypertension, nasal bleeding, asthma, hypokalemia, hyponatremia, hypomagnesemia, hypochloremic alkalosis, hypercalcemia, thrombocytopenia, leukopenia, aplastic anemia, hemolytic anemia, purpura, appetite loss, thirst, abdominal discomfort, constipation, abdominal colic, pancreatitis, jaundice, sialadenitis, dry mouth, dizziness, fatigue, drowsiness, emotional blunting, restlessness, interstitial pneumonia, pulmonary edema, acute respiratory distress syndrome, orthostatic hypotension, arrhythmia, transient vision disturbance, jaundice, choroidal exudate, hepatitis, acute cholecystitis, necrotizing vasculitis, rash, facial flushing, photosensitivity, anaphylaxis, interstitial nephritis, renal dysfunction, malaise, nasal congestion, erectile dysfunction, exacerbation of systemic lupus erythematosus with hypercalcemia, muscle cramps, sensory abnormalities, weakness, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or light, and it is best kept at room temperature between 1 degree and 25 degrees Celsius. By storing it this way, the efficacy of the medication can be maintained for a longer period.

Appearance and packaging

Appearance

Light yellow circular film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.